Digital Sleep Therapeutics, Explained: The 2026 Field Guide
What digital sleep therapeutics covers, why it matters in 2026, and the numbers decision-makers should know.
Few corners of healthcare technology are moving faster than digital sleep therapeutics. CBT-I apps and evidence-based digital sleep treatment. This explainer sets out what the category actually covers, why it has moved to the center of digital therapeutics strategy, and the numbers every decision-maker should have at hand.
What it covers
CBT-I apps and evidence-based digital sleep treatment. In practice, that spans the vendors building the technology, the health systems and payers deploying it, and the regulators writing the rules around it. The category sits inside our broader Digital Therapeutics coverage, and its daily developments stream into the live Digital Sleep Therapeutics feed.
Why it matters in 2026
Consider the current numbers: medicare DMHT patient billing grew from 99 patients in Q1 2025 to 446 by Q3 (our coverage).
Meanwhile, boehringer Ingelheim put $50 million into Click Therapeutics to commercialize its schizophrenia DTx (our coverage).
Meanwhile, a Canadian randomized trial showed digital CBT-I built for adults 65+ meaningfully cut insomnia and anxiety (our coverage).
What to watch next
Three signals will tell you where digital sleep therapeutics goes from here: the reimbursement decisions now moving through CMS and commercial payers, the consolidation pattern as larger platforms absorb point solutions, and the evidence base - peer-reviewed results increasingly separate durable categories from demo-ware.
The bottom line
The organizations that win here will be the ones that treat this as an operating discipline, not a procurement exercise. For the latest developments, follow our continuously updated Digital Sleep Therapeutics topic page.